University Hospitals is rolling out a remote patient monitoring program for hypertensive patients using HealthSnap’s platform. The Cleveland-based health system expects to enroll up to 5,000 patients by mid-2026, with plans to expand the program to other chronic conditions in the future.
CoraVie Medical CEO Aimee Garza and Dr. Michael Bloch, a hypertension specialist and clinical advisor for the startup, talk about why the healthcare industry needs a better approach to blood pressure monitoring. CoraVie is developing an implantable device that measures patients’ blood pressure, operating in a similar way to continuous glucose monitors. Watch or listen now!
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.
Some digital hypertension solutions produce meaningful clinical and economic outcomes, while others fall short, according to a new report from Peterson Health Technology Institute.
No one should ever learn about CKD after their kidneys have already failed.
The Phase 3 results for ocedurenone come less than nine months after Novo Nordisk acquired the drug from KBP Biosciences. Novo Nordisk has stopped the clinical trial in uncontrolled hypertension and chronic kidney disease, but is evaluating potential applications of the small molecule in other indications.
The KBP Biosciences drug Novo Nordisk is acquiring has reached Phase 3 testing as a potential treatment for uncontrolled hypertension and advanced chronic kidney disease. It’s the latest in a string of business deals aimed at expanding the Novo Nordisk pipeline beyond diabetes.
Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth.
Alnylam pioneered RNA interference drugs for rare disease. The biotech aims to bring RNAI to prevalent disorders and its alliance with Roche on the drug zilebesiran for hypertension better positions the company to achieve this goal.
Mineralys Therapeutics upsized its IPO, raising capital to finance clinical trial plans for a molecule that could become an alternative to currently available hypertension medicines. The Mineralys molecule takes a similar approach to a drug candidate that AstraZeneca is acquiring in a $1.3 billion deal.
Maina Bhaman, a board member of CinCor Pharma reflects on the news from Monday that AstraZeneca is acquiring the Massachusetts startup to bring another option for patients with resistant hypertension.
AstraZeneca has committed $1.3 billion to acquire CinCor Pharma, a clinical-stage biotech whose lead drug candidate has the potential to treat hypertension in a new way. In other M&A news, Ipsen and Chiesi Farmaceutici each announced acquisitions of rare disease biotechs. All three deals come with contingent value rights.
Scheduling software is helpful for wellness business owners in numerous ways. They get everything they need to create appointments, reschedule clients and track cancellations in one platform.
Cincor Pharma drug baxdrostat failed its Phase 2 test, falling short of the goal of reducing blood pressure in patients with uncontrolled hypertension. But results in a subgroup of patients showed double-digit declines, which the company said could inform the design of a Phase 3 clinical trial.
Ochsner Health recently released the results of its digital health pilot program for Medicaid patients with hypertension and type 2 diabetes. The program, which combines remote patient monitoring with personalized care teams, did an efficient job at bringing down patients’ blood pressure and hemoglobin A1c levels.
This dearth of maternity care providers is exacerbating the country’s less-than-stellar reputation for birth outcomes. In order to ensure better health for mothers and their newborns, OB-GYNs must identify risk factors that negatively impact pregnancy early on and work to maintain the whole picture of their pregnant patients' health. However, OB-GYNs aren’t incentivized to do this under a fee-for-service payment model.
Oben Health, a San Francisco-based company developing a digital treatment platform to fight heart disease without medication or surgery, recently received funding from AWS' accelerator for early-stage startups led by founders from underrepresented groups. The startup will use the money to scale its platform and help conduct a pilot program to better understand its model's clinical validity.
San Francisco-based Blumio and Saint Paul, Minnesota-based NxGenPort tied for the top prize in the Remote Patient Monitoring and Smart Devices track of INVEST Pitch Perfect, the startup competition integral to MedCity News' INVEST conference. Here is an in-depth look at each company.